This is an Accepted Manuscript, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication. Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this Accepted Manuscript with the edited and formatted Advance Article as soon as it is available. You can find more information about Accepted Manuscripts in the Information for Authors. Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal’s standard Terms & Conditions and the Ethical guidelines still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains.
Rh(III)-catalyzed C−H activation/cyclization of oximes with alkenes for regioselective synthesis of isoquinolines

Renjie Chen, Jifeng Qi, Zhenjun Mao, and Sunliang Cui*

A Rh(III)-catalyzed C−H activation/cyclization of oximes and alkenes for facile and regioselective access to isoquinolines has been developed. This protocol is featured with mild reaction conditions and easy accessible starting materials, and has been applied to concise synthesis of Moxaverine. Kinetic isotope effect study was conducted and a plausible mechanism was proposed.

Isoquinoline represents an important class of structural motifs existing in numerous pharmaceuticals, natural products and ligands. Therefore, various methods have been developed for accessing those compounds. In recent years, the transition-metal-catalyzed C−H activation/cyclization of aryl oximes, imines, azides with internal alkynes has been explored for the achievement of isoquinolines (Fig 1a). However, these protocols suffer from difficult regiocontrol. Recently, Glorius (Fig 1b) and Cheng (Fig 1c) have independently found that 1,3-dienes and geminal-substituted vinyl acetate could serve as cyclization partners in Rh(III)-catalysis for regioselective synthesis of isoquinolines. Despite these advances, the development of general and efficient method for the construction of these compounds, especially with good regioselectivity and broad functional group tolerance, still remains important and interesting, since various privileged biologically interesting isoquinolines bear functional groups like ketone.

Recently, Rovis reported Rh(III)-catalyzed C−H activation/cyclization of oxime esters and alkenes for accessing pyridines, indicating that alkenes act as a coupling component in the cyclization process and could probably be applied to isoquinoline synthesis. In continuation of our interests in Rh(III)-catalyzed C−H functionalization for biologically interesting small molecule synthesis, herein, we would like to report a Rh(III)-catalyzed C−H activation/cyclization of oximes with alkenes for regioselective synthesis of isoquinolines, and its application in total synthesis of Moxaverine (Fig. 1d).

We commenced our study by investigating oxime 1a and acrolein 2a, with [Cp*RhCl₂]₂ as catalyst and the addition of PivOH at room temperature in the solvent of CH₃CN. With the addition of 2 equivalent amount of CsOAc, we were pleased to...
find that the isoquinoline product 3a was formed and isolated in 43% yield (Table 1, entry 1). The formation of 3a indicated a C−H activation/cyclization occurring in the process. This encouraged us to further screen the additives, and Cu(OAc)$_2$ was found inferior to shut down the reactivity (entry 2). We next turn to screen the silver salts and found that AgOAc was optimal to increase the yield to 57% (entry 3). The use of AgBF$_4$ and Ag$_2$O were found to further improve the yield (entries 4 and 5). Gratifyingly, the addition of Ag$_2$CO$_3$ as additive was superior, leading to a dramatic improvement of the yield to 84% (entry 6).

Control reaction showed that the removal of PivOH would completely shut down the reactivity, demonstrating the importance of PivOH (entry 7). The solvent screening showed that DCE, MeOH and THF were not effective, resulting trace product formation (entries 8-10). Other oximes such as O-methyl oxime 4 and O-pivaloyl oxime 5 were also tested and found not applicable in this protocol (Fig. 2).

Table 1. Optimization of reaction conditions.$^a$

<table>
<thead>
<tr>
<th>entry</th>
<th>additive</th>
<th>solvent</th>
<th>yield (%)$^b$</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>CsOAc (2 equiv)</td>
<td>CH$_3$CN</td>
<td>43</td>
</tr>
<tr>
<td>2</td>
<td>Cu(OAc)$_2$ (2 equiv)</td>
<td>CH$_3$CN</td>
<td>trace</td>
</tr>
<tr>
<td>3</td>
<td>AgOAc (2 equiv)</td>
<td>CH$_3$CN</td>
<td>57</td>
</tr>
<tr>
<td>4</td>
<td>AgBF$_4$ (2 equiv)</td>
<td>CH$_3$CN</td>
<td>60</td>
</tr>
<tr>
<td>5</td>
<td>Ag$_2$O (2 equiv)</td>
<td>CH$_3$CN</td>
<td>69</td>
</tr>
<tr>
<td>6</td>
<td>Ag$_2$CO$_3$ (2 equiv)</td>
<td>CH$_3$CN</td>
<td>84</td>
</tr>
<tr>
<td>7*</td>
<td>Ag$_2$CO$_3$ (2 equiv)</td>
<td>CH$_3$CN</td>
<td>trace</td>
</tr>
<tr>
<td>8</td>
<td>Ag$_2$CO$_3$ (2 equiv)</td>
<td>DCE</td>
<td>trace</td>
</tr>
<tr>
<td>9</td>
<td>Ag$_2$CO$_3$ (2 equiv)</td>
<td>MeOH</td>
<td>trace</td>
</tr>
<tr>
<td>10</td>
<td>Ag$_2$CO$_3$ (2 equiv)</td>
<td>THF</td>
<td>trace</td>
</tr>
</tbody>
</table>

$^a$Reaction conditions: 1a (0.2 mmol), 2a (0.6 mmol), [Cp*RhCl$_2$]$_2$ (2 mol %), PivOH (0.4 mmol), solvent (1 mL), RT, 18 h. $^b$Yields of isolated product. $^c$Without PivOH.

With the optimized reaction condition in hand, we next investigated the generality of the reaction (Scheme 1). Various aromatic oximes with valuable functional groups on the aromatic ring, such as methyl, benzyloxy, chloro, bromo, nitro, amino, could react smoothly with acrolein 2a to afford the corresponding products (3b-3g) in moderate to excellent yields (56%-95%), thus offering ample opportunity for further derivation. Additionally, when a meta substituted oxime 1h was used, the reaction afforded a separable mixture of isoquinoline products 3ha and 3hb. When the substitution is varied on the methyl group, a variety of functional groups were tolerated in this process. For example, the groups like ethyl, benzyl, sulfone, phenyl, were well applicable in this cyclization to furnish the structural different isoquinolines (3i-3m). Interestingly, the ketone and ester substituted oximes were also applicable in this process to furnish the products in good yields (3n and 3o). It should be noted that 3j and 3n are the core structures of Moxaverine and Pulcheotine to demonstrate the synthetic utility. Moreover, the bicyclic oxime 1p could also proceed well to deliver tricyclic product in moderate yield (3p, 55%). Next, we test the substrate scope of alkenes. The acrylates and acrylamides could proceed well in this process to generate the products in moderate to excellent yields (3q-3t) under a slightly modified reaction condition. Furthermore, a variety of vinyl ketones were also tested and found tolerable in this process to furnish the isoquinolines (3u-3x), with the valuable substitution like furan and thiophene.

Considering the wealth of isoquinoline in natural products and
pharmaceuticals, this method provides a direct approach toward the achievement of these heterocycles from readily available starting materials under mild reaction conditions.

Next, the synthetic utility of this protocol was further demonstrated by concise synthesis of Moxaverine, a drug used to treat functional gastrointestinal disorders (Fig. 3). Initially, the simple phenylacetic acid was converted to phenylacetyl chloride, which underwent a Friedel-Crafts reaction with 1,2-dimethoxybenzene to afford 6. 6 was then converted to oxime 7 and subject to the standard reaction condition with methyl vinyl ketone to deliver isoquinoline 8. The next transformation of ketone to tosyl hydrazone and a following DIBAL-reduction finally furnished Moxaverine in 65% yield.

To gain insight to the reaction mechanism, kinetic isotope effect (KIE) study was conducted (Fig. 4), and a large primary KIE value (2.8) was obtained, suggesting that C–H bond cleavage occurs during the rate-determining step.

Based on the experiments and literature precedents, a plausible mechanism is proposed in Fig. 4. The initial [Cp*Rh(I)] was generated from [Cp*RhCl₂] and Ag₂CO₃, and reacted with oxime 1 with a C–H activation/cyclorhodation step to afford intermediate A, which is coordinated with alkene 2 to form complex B. The sequential regioselective insertion of alkene from B led to intermediate C, and a redox-neutral cyclization furnished D and Rh(I). The reduction of D by Rh(I) regenerates [Cp*Rh(I)] catalyst to enable the catalytic cycle and also delivers dihydroisoquinoline species E. Finally, the oxidation of E by Ag₂CO₃ delivered the aromatic isoquinoline products 3, thus the amount of Ag₂CO₃ should be equivalent.

In summary, a Rh(III)-catalyzed C–H activation/cyclization of oximes and alkenes has been developed for regioselective synthesis of isoquinolines. The protocol is featured with broad substrate scope and mild reaction conditions, and also applied to concise synthesis of Moxaverine. Furthermore, kinetic effect study was conducted and a plausible mechanism was proposed.

This work was financially supported by National Natural Science Foundation of China (grant no 21472163).

Notes and references


2. (a) A. Bischler, B. Napieralski, Chm. Ber., 1893, 26, 1503; (b) A. Pictet, T. Spengler, Chem. Ber., 1911, 44, 2030.


